MARKET

SAGE

SAGE

SAGE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

82.70
+2.82
+3.53%
After Hours: 82.70 0 0.00% 17:25 11/25 EST
OPEN
79.48
PREV CLOSE
79.88
HIGH
83.27
LOW
79.48
VOLUME
579.67K
TURNOVER
--
52 WEEK HIGH
155.33
52 WEEK LOW
25.01
MARKET CAP
4.30B
P/E (TTM)
-7.9869
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Jefferies sees outsize upside in its highest-conviction SMID-cap picks
Small and mid-cap equities have been bouncing - but they have nearly two years of underperformance to make up, says a bullish Jefferies, weeding through the Russell 2000 for the
Seekingalpha · 5d ago
Positive catalysts for Sage Therapeutics called out by Oppenheimer
Oppenheimer thinks pipeline catalysts could unlock value for Outperform-rated Sage Therapeutics (SAGE). The firm sees value in SAGE-324 (GABAA PAM) in Essential Tremor and SAGE-718 (NMDA PAM) in certain MCI
Seekingalpha · 11/19 13:18
Some Analysts Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Estimates
Simply Wall St. · 11/18 05:04
Morgan Stanley Downgrades Sage Therapeutics to Equal-Weight, Announces $85 Price Target
Morgan Stanley analyst Matthew Harrison downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Equal-Weight and announces $85 price target.
Benzinga · 11/16 11:45
Sage Therapeutics, Inc. (NASDAQ:SAGE) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a good week for Sage Therapeutics, Inc. (NASDAQ:SAGE) shareholders, because the company has just released...
Simply Wall St. · 11/09 13:26
Sage Therapeutics Q3 Earnings Preview
Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is -$2.47 (+29.0% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 11/04 16:37
Sage Therapeutics Announces Chief Executive Jeff Jonas to Undergo Scheduled Medical Procedure
Business Wire · 10/22 10:30
We're Not Very Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 10/21 16:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SAGE. Analyze the recent business situations of SAGE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SAGE stock price target is 97.16 with a high estimate of 190.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 425
Institutional Holdings: 63.30M
% Owned: 121.63%
Shares Outstanding: 52.04M
TypeInstitutionsShares
Increased
70
2.67M
New
63
1.69M
Decreased
74
4.70M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Director
Kevin Starr
President/Chief Executive Officer/Director
Jeffrey Jonas
Chief Financial Officer/Treasurer
Kimi Iguchi
Chief Operating Officer
Michael Cloonan
Senior Vice President/General Counsel/Secretary
Anne Cook
Chief Scientific Officer
Albert Robichaud
Other
Stephen Kanes
Director
Barry Greene
Independent Director
Elizabeth Barrett
Independent Director
Michael Cola
Independent Director
James Frates
Independent Director
Geno Germano
Independent Director
George Golumbeski
Independent Director
Asha Nayak
Independent Director
Steven Paul
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SAGE
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SAGE Therapeutics Inc stock information, including NASDAQ:SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.